Physician profile
Peter P Chang
NPI 1780688028
$20,211.71
in general payments reported to CMS, 2019-2025
45 companies · $5,662 in 2025
The $5,662 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $1,402 · 2021: $1,284 · 2022: $1,150 · 2023: $727 · 2024: $9,488 · 2025: $5,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $2,357 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,500.00 |
| Food and Beverage | $2,357.08 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,004.78 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $932.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $682.81 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $441.42 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Ardelyx, INC. | $388.07 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $295.32 | 2019-2022 | |
| Allergan, INC. | $289.17 | 2019-2022 | |
| Glaxosmithkline, LLC. | $203.17 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $169.44 | 2019-2021 | |
| New World Medical,INC. | $127.34 | 2022 | |
| Amgen INC. | $116.10 | 2020-2025 | Repatha, Otezla, Otezla |
| Biohaven Pharmaceuticals, INC. | $114.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.00 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $99.19 | 2019-2021 | |
| Amarin Pharma, INC. | $98.34 | 2020-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.